Pfizer COVID-19 vaccine safety data - People affected by cancer and transplant recipients Pfizer COVID-19 vaccine adult formulation Main navigation COVID-19 vaccines Pfizer JN.1 COVID-19 vaccine safety data – all participants Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Pfizer XBB.1.5 COVID-19 vaccine Moderna XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Pregnant participants Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix AusVaxSafety has been actively monitoring the short-term adverse event profile of COVID-19 vaccines used in Australia through post-vaccination safety surveys that allow vaccine recipients to report any adverse events they may have experienced at different intervals following vaccination. These surveys also allow individuals to report pre-existing medical conditions, allowing AusVaxSafety to capture COVID-19 vaccine safety data, specific to Australia, for people affected by cancer and transplant recipients.AusVaxSafety captures COVID-19 vaccine safety data for the following cancer and transplant recipient population groups:cancer (not including blood or bone marrow cancer) diagnosed in the last 12 monthsblood cancer (e.g. leukaemia, lymphoma or myelodysplastic syndrome) diagnosed within the last 5 yearsorgan transplant recipients on immune suppressive therapy or bone marrow transplant recipients in the last 2 yearsAusVaxSafety has analysed the data collected from people who reported the above pre-existing conditions and have created infographics outlining the short-term adverse event profile for each group, including a comparison to the general population. These infographics provide individuals affected by cancer and transplant recipients with real-world information on what to expect following Pfizer COVID-19 vaccination and can be used when planning for COVID-19 vaccination.AusVaxSafety has reaffirmed the safety of these vaccines. Data on this page will no longer be updated. Find out more here. Cancer (not including blood or bone marrow cancer) The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than EnglishAustralian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021Guidance on myocarditis and pericarditis after COVID-19 vaccinesComirnaty vaccine phase III trial publication Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publicationAusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. Blood cancer The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than EnglishAustralian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021Guidance on myocarditis and pericarditis after COVID-19 vaccinesComirnaty vaccine phase III trial publication Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. Organ transplant or bone marrow transplant recipient The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than EnglishAustralian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021Guidance on myocarditis and pericarditis after COVID-19 vaccinesComirnaty vaccine phase III trial publication Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. News & events All news & events 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations 18 May 2025 | News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination 31 March 2025 | News AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines